Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPP Adherence and Acceptability Study
NCT04778527Active, not recruiting
- Sponsor
- Population Council
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Dual Prevention Pill in human immunodeficiency virus infection (HIV) and unintended pregnancy (2 arms), sponsored by Population Council. Primary endpoints: Adherence to the DPP capsule versus 2 separate tablets, Adherence among women who choose the DPP capsule versus 2 separate tablets and 2 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
Dual Prevention Pill
03
Conditions
human immunodeficiency virus infection (HIV)unintended pregnancy
Beyond the preview
Go deeper on NCT04778527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778527.